已发表论文

RNA 或蛋白质生物标志物在前列腺癌诊疗中的研究现状和进展

 

Authors Song C, Chen H, Song C

Received 10 November 2018

Accepted for publication 1 February 2019

Published 22 March 2019 Volume 2019:12 Pages 2123—2136

DOI https://doi.org/10.2147/OTT.S194138

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 5

Editor who approved publication: Dr Sanjeev Srivastava

Abstract: Prostate cancer is a kind of male malignancy. Recently, a large number of studies have reported many potential biomarkers for the diagnosis and prognosis of prostate cancer. In this literature review, we have collected a number of potential biomarkers for prostate cancer reported in the last 5 years. Among them, some are undergoing Phase III clinical trials, and others have been approved by the US Food and Drug Administration. However, most are still in the period of basic research. The review will contribute to future research to find the biomarkers to guide clinicians to make personalized treatment decisions for each prostate cancer patient.
Keywords: lncRNAs, microRNAs, fusion gene, TMPRSS2-ERG, methylation



Table 1 The list of the biomarkers for prostate cancer